HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Pentoxifyllin
PTX · PENTOXYFYLLINE · 3,7-Dimethyl · 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione · TRENTAL · PENTOXIFYLINE · oxpentifylline · Pentoxyfilline
Identifikatoren & physikalische Daten
| CAS No. | 6493-05-6 |
|---|---|
| Summenformel | C13H18N4O3 |
| Durchschnittliche Molmasse | 278,31 g/mol |
| Monoisotopische Masse | 278,13789045 g/mol |
| SMILES | CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O |
| InChIKey | BYPFEZZEUUWMEJ-UHFFFAOYSA-N |
| PubChem CID | 4740 |
| ChEMBL | CHEMBL628 |
| ChEBI | CHEBI:7986 |
| EC No. | 229-374-5 |
| DTXSID | DTXSID7023437 |
| Lokaler Name | Pentoxifyllin |
Chemische & physikalische Eigenschaften
| XLogP | 0,3 |
|---|---|
| Polarare Oberfläche (TPSA) | 75,5 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 5 |
| Schwere Atome | 20 |
| Formalladung | 0 |
| Komplexität | 426 |
| Stoffklassen | Pharmaceutical |
| Arzneimittel | PharmaceuticalPharmaceuticals -> Listed in ZINC15Pharmaceuticals -> Used in Switzerland |
| LogP (Verteilungskoeffizient) | 0.29 |
| Löslichkeit | 5.17e+00 g/LH2O: ≥43 mg/mLH2O: ≥43mg/mL, colorless to almost colorless |
| Human Drugs | Breast FeedingLactationHematologic AgentsPhosphodiesterase InhibitorsPlatelet Aggregation InhibitorsXanthinesFDA approved drugs -> Active ingredientPharmaceuticals |
| Schmelzpunkt | 105 °C98-100°C |
| Physical Description | Solid |
| Ionization Efficiency | Positive2.072.7Agilent XCTElectrospray ionizationformic acid (5.3nM) |
| Collision Cross Section | 172.0 Ų [M+Na]+ [CCS Type: DTBuffer gas: N2Ionization: ESI+Dataset: TOXCASTSource Identifier: DTXSID7023437]158.5 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]167.95 Ų [M+Na]+ [CCS Type: TW |
| Siedepunkt | 421.13°C (rough estimate) |
| Dichte | 1.1713 (rough estimate) |
| Brechungsindex | 1.6000 (estimate) |
| Lagerbedingungen | Sealed in dry,Room Temperature |
| Aggregatzustand | solid |
| pKa (Säurekonstante) | 0.50±0.70(Predicted) |
| Farbe | white |
| Merck | 14,7136 |
| Hauptanwendungen | pharmaceutical (small molecule) |
| InChI | 1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8,10-11H,4-7H2,1-3H3 |
| InChIKey | MQGNNJQTNFHNHK-UHFFFAOYSA-N |
| SMILES | CN1C=NC2C1C(=O)N(CCCCC(C)=O)C(=O)N2C |
| CAS Datenbank | 6493-05-6(CAS DataBase Reference) |
| NIST chemische Informationen | Pentoxifylline(6493-05-6) |
| EPA chemische Informationen | 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- (6493-05-6) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 4.5% (3 of 67) of reports.WarningH302 (95.5%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 67 reports by companies from 5 notifications to the ECHA C&L Inventory. |
|---|---|
| Weitere Sicherheitsinformationen | IMAP assessments - 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-: Human health tier I assessment |
| Hazard Classes and Categories | Acute Tox. 4 (95.5%) |
| Hepatotoxicity | Chronic therapy with pentoxifylline has not been associated with elevations in serum enzyme levels, although the rigor with which liver test abnormalities were sought in patients taking the drug was not always clear. Despite its use for more than 3 decades, pentoxifylline has been linked to only rare and not completely convincing cases of clinically apparent liver injury. Nevertheless, adverse effects of hepatitis, jaundice, cholestasis and increased liver enzymes are listed in product labels for pentoxifylline. In reported cases, the time to onset was 3 to 4 weeks and the pattern of liver enzyme elevations was distinctly cholestatic (Case 1). Autoimmune and immunoallergic features were not present. The injury was self-limited and there have been no reports of acute liver failure, chronic hepatitis or vanishing bile duct syndrome associated with pentoxifylline therapy. |
| Unerwünschte Wirkungen | The most common adverse effect of pentoxifylline is nausea and vomiting. Other common adverse drug reactions are listed below. |
| Toxizitätsübersicht | Signs and Symptoms of Overdose |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)PentoxifyllineAmbiguous-DILI-concern5Adverse reactionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| USGS Health-Based Screening Levels for Evaluating Water-Quality | PentoxifyllinePharmaceuticalSmith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP |
| EPA Human Health Benchmarks for Pharmaceuticals | Pentoxifylline28.0118.3The usual dosage of pentoxifylline in extended-release tablet form is one tablet (400 mg) three times a day with meals.Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 1200 mg/day, Lowest Therapeutic Dose (LTD): 15.0 mg/kg-day, and Screening Dose: 0.005 mg/kg-day.19-Nov-19 |
| Wassergefährdungsklasse (WGK) | 3 |
| Zollcode | 2939590000 |
| RTECS-Nr. | XH2475000 |
| R-Sätze (R) | 22 |
| Toxizität | LD50 orally in mice: 1385 mg/kg (Popendiker) |
| Gefahrensymbole | Xn |
| Sicherheitshinweise (S) | 36 |
| Lagerklasse | 11 - Combustible Solids |
| Gefahrenklasse | Acute Tox. 4 OralLact. |
Anwendungen & Verwendung
Verwenden
Pentoxifylline is a methylxanthine phospho-diesterase inhibitor with favorable antiinflammatory effects and immunoregulatory properties.A metabolite of Pentifylline. Methylxanthine derivative that improves blood flow by decreasing blood viscosity. Phosphodiesterase inhibitor. Inhibits the synthesis of tumor necrosis factor a (TNF-a).